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Abstract
Background/Aims: Flow restoration to ischemic myo-
cardium reduces infarct size (IS), but it also promotes
reperfusion injury. A burst of reactive oxygen species
(ROS) and/or NHE-1 reactivation were proposed to
explain this injury. Our study was aimed to shed light
on this unresolved issue. Methods: Regional infarc-
tion (40 min-ischemia/2 hs-reperfusion) was induced
in isolated and perfused rat hearts. Maximal doses of
N-(2-mercaptopropionyl)-glycine (MPG 2mmol/L, ROS
scavenger), cariporide (10µmol/L, NHE-1 inhibitor),
or sildenafil (1µmol/L, phosphodiesterase5A inhibi-
tor) were applied at reperfusion onset. Their effects
on IS, myocardial concentration of thiobarbituric acid
reactive substances (TBARS), ERK1/2, p90RSK, and
NHE-1 phosphorylation were analyzed. Results: All
treatments decreased IS ~ 50% vs. control. No fur-
ther protection was obtained by combining cariporide
or MPG with sildenafil. Myocardial TBARS increased
after infarction and were decreased by MPG or
cariporide, but unaffected by sildenafil. In line with
the fact that ROS induce MAPK-mediated NHE-1 ac-
tivation, myocardial infarction increased ERK1/2,
p90RSK, and NHE-1 phosphorylation. MPG and
cariporide cancelled these effects. Sildenafil did not
reduce the phosphorylated ERK1/2-p90RSK levels but
blunted NHE-1 phosphorylation suggesting a direct
dephosphorylating action. Conclusions: 1)
Reperfusion injury would result from ROS-triggered
MAPK-mediated NHE-1 phosphorylation (and reacti-
vation) during reperfusion; 2) sildenafil protects the
myocardium by favouring NHE-1 dephosphorylation
and bypassing ROS generation.
Introduction
Following an acute myocardial infarction (MI), early
coronary artery reperfusion remains to be the most ef-
fective intervention to decrease infarct size (IS), which
is a major determinant of the patient’s clinical outcome.
However, the process of restoring blood flow to the
ischemic zone induces cellular injury and cardiomyocyte
death, thus increasing IS and reducing the beneficial ef-
fect of reperfusion. Reperfusion injury may explain why,
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despite early myocardial reperfusion, IS as well as the
incidence of heart failure is still elevated, and why sev-
eral therapeutic strategies are addressed to its decrease.
The reactive oxygen species (ROS) burst at the be-
ginning of reperfusion and cytosolic Ca2+ overload are
two proposed mechanisms to explain cell injury. It is dif-
ficult to separate cause-and-effect relationship between
these variables, since ROS by activating kinases upstream
the cardiac Na+/H+ exchanger (NHE-1) may induce Ca2+
overload, and both ROS and Ca2+ are known to be me-
diators in the regulation of mitochondrial permeability tran-
sition pore (MPTP) formation [1], a key step in the proc-
ess of reperfusion injury.
Inhibition of NHE-1 is one of the most powerful in-
terventions known to protect the heart against ischemia/
reperfusion injury in experimental animal models [2-8].
Phosphodiesterase 5A (PDE5A) inhibitors also emerged
as powerful preconditioning-like, cardioprotective agents
that decrease IS [9-11]. PDE5A hydrolyses the
phosphodiester bond of cyclic GMP increasing the intra-
cellular concentration of cGMP with the consequent ac-
tivation of PKG. In a recent study, we reported that chronic
treatment with the PDE5A inhibitor, sildenafil (SIL), was
able to improve post MI remodeling and function [12].
The beneficial effect of SIL was accompanied by
activation of protein kinase G (PKG) and inhibition of
NHE-1. The ability of cGMP/PKG to inhibit the NHE
was previously demonstrated in tissues other than myo-
cardium [13-16]. Moreover, we recently reported in
mammalian myocardium that the effect of PDE5A
inhibitors on NHE-1 activity was linked to a PKG-medi-
ated phosphatase activation that dephosphorylates the
exchanger [17, 18]. Taken together, these data suggest
that the acute beneficial effects of both NHE-1 and
PDE5A inhibitors upon ischemia/reperfusion injury would
be a linked phenomenon.
Experiments in which IS was measured after
ischemia and reperfusion were performed, and the ef-
fects of three pharmacological interventions (NHE-1 in-
hibition, ROS scavenging and PDE5A inhibition) initiated
during the early phase of reperfusion were compared.
We provide evidence supporting the idea that the three
of them reduce IS by converging at a common step the
prevention of NHE-1 activation.
Materials and Methods
All procedures followed during this investigation con-
form to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH Publi-
cation No. 85-23, revised 1996) and to the guidelines laid down
by the Animal Welfare Committee of La Plata School of Medi-
cine.
Isolated heart preparation
Hearts from male Wistar rats were isolated and
Langendorff perfused with Ringer’s solution containing (in
mmol/L) 118 NaCl, 5.9 KCl, 1.2 MgSO4, 1.35 CaCl2, 20 NaCO3H
and 11.0 glucose (gassed with 95% O2-5% CO2, pH 7.4, 37°C),
as described elsewhere [19].
Experimental protocols
MI was induced after 20 min of stabilization by occluding
the left anterior descending coronary artery (LAD) during
40 min followed by 120 min of reperfusion. During the first 20
min of reperfusion the following interventions were applied:
(1) preischemic solution (no pharmacological intervention);
(2) specific NHE-1 blockade with cariporide (10 μmol/L); (3)
ROS scavenging with MPG (2 mmol/L); (4) PDE5A inhibition
with SIL (1 µmol/L); (5) combination of SIL (1 µmol/L)
+ cariporide (10 μmol/L); (6) combination of SIL (1 μmol/L)
+ MPG (2 mmol/L).
IS determination
IS was assessed by the tripenyltetrazoliumchloride (TTC)
staining technique [20]. At the end of reperfusion, the LAD
was occluded again and the myocardium was perfused during
1 min with a 0.1 % solution of Evans blue. This procedure
delineated the non-ischemic myocardium as dark blue. After
staining, the hearts were frozen and cut into six transverse
slices, which were incubated for 5 minutes at 37°C in 1% solu-
tion of TTC. All atrial and right ventricular tissues were ex-
cised. To measure myocardial infarction, the slices were weighed
and scanned. The infarcted (pale), viable ischemic/reperfused
(red), and non-ischemic (blue) areas were measured by com-
puted planimetry (Scion Image 1.62; Scion Corp., Frederick,
Maryland, USA). By TTC technique non-infarcted viable myo-
cardium containing dehydrogenase stained brick red; whereas
the infarcted tissue remained unstained because of the lack of
the enzyme. According to previous data [21], the reperfusion
time used in this study is enough to minimize the presence of
pink-and-white area patches which difficult the accuracy of IS
measurements. The area at risk (AAR) was the portion of the
left ventricle supplied by the previously occluded coronary
artery identified by the absence of blue dye. Infarct weights
were calculated as (A1 × W1) + (A2 × W2) + (A3 × W3) + (A4
× W4) + (A5 × W5) + (A6 × W6), where A is the area of infarct
in the slice and W is the weight of the respective section. The
weight of the AAR was calculated in a similar fashion. IS was
expressed as a percentage of AAR.
Systolic and diastolic function
Myocardial contractility was evaluated by the
isovolumetric left ventricular developed pressure (LVDP), and
calculated by subtracting left ventricular end diastolic pres-
sure (LVEDP) from the LV peak pressure values, and the maxi-
mal velocity of rise of LVP (+dP/dtmax). Data are expressed as
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percent of the corresponding pre-ischemic control values.
Diastolic function was evaluated by isovolumetric LVEDP.
Assessment of lipid peroxidation
We used the thiobarbituric acid reactive substances
(TBARS) spectroscopic technique [22] to evaluate lipid
peroxidation as index of ROS formation. Briefly, in separated
groups of hearts subjected to the same protocols at the end of
the reperfusion period cardiac tissue was homogenized in physi-
ological saline solution and centrifuged at 2500 rpm to allow
measuring TBARS in the supernatant. Absorbance at 535nm
was measured and TBARS expressed in nmol/g of tissue using
an extinction coefficient of 1.56x105 M-1cm-1.
Preparation of cardiac slices
Hearts were quickly removed from previously
anesthetized animals and perfused through the aorta with Ringer
buffer pH 7.4 to eliminate blood. Tissue slices from the left
ventricle (1x5 mm) were cut and kept at 4°C until assayed. As-
say buffer consisted of Krebs-Hepes buffer of the following
composition in mmol/L: 118.3 NaCl; 4.7 KCl; 1.8 CaCl2; 1.2
MgSO4; 1.0 K2HPO4; 25 NaHCO3; 11 glucose; 20 HEPES (pH
7.4 after 1.5 h gassed with 95% O2-5% CO2, pH 7.4, 37°C). Car-
diac tissue was incubated in the assay buffer during 30 min in
the presence of different drugs in a metabolic incubator under
95% O2/ 5% CO2 at 37 °C before measurements of superoxide
anions (·O2-) production.
Measurements of ·O2- production
We used lucigenin-enhanced chemiluminescence to meas-
ure ·O2- production by rat cardiac slices in Krebs-Hepes buffer
with 5 μmol/L lucigenin. Chemiluminescence (arbitrary units,
AU) was recorded with a luminometer (Chameleon, Hidex) dur-
ing 30 seconds every 4.5-min during 30 min. The lucigenin-
containing assay buffer with tissue slices minus background,
as well as responses to the different drugs assayed were re-
ported. ·O2- production was normalized to mg dry weight tissue
per minute. Control tissue slices without pharmacological in-
tervention produced low levels of ·O2- which were only slightly
above background. The increase in ·O2- production was ex-
pressed as percent of basal value after 15 minutes of each
intervention.
Determination of extracellular signal-regulated protein
kinases (ERK1/2) and p90 ribosomal S6 kinase (p90RSK)
Cardiac tissue was homogenized in lysis buffer (300
mmol/L sucrose; 1 mmol/L DTT; 4 mmol/L EGTA, protease in-
hibitors cocktail (Complete Mini Roche); 20 mmol/L Tris-HCl,
pH 7.4). After a brief centrifugation the supernatant was kept
and protein concentration determined by the Bradford method.
Samples were denatured and equal amounts of protein sub-
jected to PAGE and electrotransferred to PVDF membranes.
After blocking with non-fat-dry milk, membranes were incu-
bated overnight either with anti-phospho-ERK1/2 or anti-
phospho- p90RSK polyclonal antibodies (Santa Cruz Biotech-
nology). A peroxidase-conjugated anti-rabbit IgG (Santa Cruz
Biotechnology) was used as secondary antibody. Bands were
visualized using the ECL-Plus chemiluminescence detection
system (Amersham). Autoradiograms were analyzed by
densitometric analysis (Scion Image). GAPDH signal was used
as a loading control.
NHE-1 phosphorylation
NHE-1 phosphorylation was estimated in NHE-1
immunoprecipitated samples using an anti-P-14-3-3 protein
binding motif antibody as previously described [17, 23]. It has
been shown that the regulatory Ser703 in the NHE-1 lies within
a sequence which creates a binding motif for 14-3-3 proteins
upon ERK/p90RSK phosphorylation; thus, the phospho-Ser 14-
3-3 binding motif antibody represents a useful tool for estimating
NHE-1 Ser703 phosphorylation [24-26]. Briefly, ventricular
myocardium was homogenized in lysis buffer at pH 7.5
containing (in mmol/L) Tris-HCl 50, EGTA 5, EDTA 2, NaF 100,
and Na3VO4 1, as well as 0.05% digitonin and protease inhibitor
cocktail (Complete Mini, Roche). The homogenate was then
centrifuged at 14,000 × g for 30 min at 4 °C and the supernatant
discarded. The pellet was then solubilized in ice-cold
immunoprecipitation lysis buffer at pH 7.5 containing (in mmol/
L) Tris-HCl 20, NaCl 150, EDTA 1, EGTA 1, sodium
pyrophosphate 2.5, β−glycerophosphate 1, Na3VO4 1, and NaF
100, as well as 1% Triton X-100 and protease inhibitor cocktail
(Roche). The samples were centrifuged at 14,000 × g for 60 min
at 4 °C, after which the supernatant containing the solubilized
membranes was removed and protein concentration determined
by the Bradford assay. Fixed amounts of protein (400 µg) were
then incubated with rabbit polyclonal NHE-1 antibody (4 µL;
Millipore) for 3 hs. at 4 ºC . Then, immune complexes were
mixed with protein A/G Plus-Agarose (Santa Cruz
Biotechnology, Inc.) for 3 h at 4 °C and washed three times with
ice-cold immunoprecipitation buffer. The immune complexes
were dissociated by the addition of Laemmli sample buffer and
heating for 3 min at 60 °C. Proteins were resolved on 7 % SDS-
PAGE and analyzed by Western immunoblotting using mouse
polyclonal phospho-(Ser) 14-3-3 binding-motif protein antibody
(Cell Signaling). Peroxidase-conjugated anti-rabbit (Santa Cruz
Biotechnology) was used as secondary antibody and bands
were visualized using the ECL-Plus chemiluminescence
detection system (Amersham). After stripping, the same
membrane was re-probed with anti- NHE antibody, and results
shown as the ratio of phosphorylated to total protein.
Autoradiograms were analyzed by densitometric analysis
(Scion Image).
Chemicals
All drugs used in the present study were of analytical
grade. Ang II, lucigenin and N-(2-mercaptopropionyl)-glycine
(MPG) were purchased from Sigma; cariporide (Aventis);
SIL was generously donated by Roemmers Argentina. Either
assay buffer or dimethyl sulfoxyde (DMSO) was used to
prepare the drugs. For the ·O2- assay final DMSO concentra-
tion was kept <0.5% which did not interfere with the lucigenin
signal.
Statistics
Results are presented as mean±SEM. Statistical analysis
was performed using the Student’s t-test or one-way ANOVA
Reactive Oxygen Species, NHE-1 and Reperfusion Injury Cell Physiol Biochem 2011;27:13-22
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followed by the Student-Newman-Keuls test, when necessary.
P<0.05 was considered significant.
Results
Forty minutes of regional ischemia followed by 2
hours of reperfusion in rat hearts without any treatment
caused an IS of ~30 % of the AAR (Fig. 1). The AAR
for all interventions was similar and represented ~32 %
of the left ventricle. A significant reduction in IS was
obtained when 10 µmol/L cariporide was added to the
perfusate during the first 20 minutes of reperfusion
(Fig. 1), a result in agreement with previous reports [19,
27-29].
Animal studies have demonstrated an increase in
ROS generation following reperfusion, with a burst that
peaks 2-3 minutes after reflow and lasts for about 20
minutes [30-32]. However, the beneficial effect of scav-
engers or antioxidants during reperfusion is still contro-
versial [33-37]. In our hands, when ROS production was
mitigated by reperfunding the hearts in the presence of 2
mmol/L MPG (ROS scavenger), a reduction in IS of simi-
lar magnitude to that observed after cariporide was
achieved (Fig. 1).
Since PDE5A inhibitors were shown to possess pow-
erful cardioprotective properties in ischemia/reperfusion
[9-12], we next explored whether SIL could also decrease
IS when administered early in the reperfusion. As shown
in Figure 1, SIL (1 µmol/L) reduced the IS similarly to the
other two pharmacological interventions used. Interest-
ingly, the combination of SIL and cariporide or SIL and
MPG did not reduce the IS further (Fig. 1), suggesting
that the three interventions probably targeted a common
signalling pathway to protect the heart against reperfusion
injury.
Fig. 2 shows the effects of the interventions explored
on systolic myocardial function. At the end of the
Garciarena/Fantinelli/Caldiz/Chiappe de Cingolani/Ennis/Pérez/
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Fig. 1. Forty minutes of regional ischemia followed by 2 hours
of reperfusion in the rat myocardium produced an IS of
~30 % of the AAR (I/R). Cariporide, MPG, or SIL reduced IS
to a similar extent (~50% less than for non-treated hearts).
Combinations of SIL with either cariporide or MPG did not
induce further reduction in IS. Original TTC-stained cross
sectional slices from a representative heart of each experimen-
tal protocol are displayed on top of the corresponding aver-
aged bar graph. * P < 0.05 vs. I/R.
Fig. 2. Left ventricular developed pressure (LVDP) and maximal
rise velocity of LVP (+dP/dtmax) at the end of the reperfusion
period (expressed as a percentage of preischemic values) in all
experimental groups. All interventions improved postischemic
myocardial systolic function to a similar extent compared to
non treated I/R. * P < 0.05 vs. I/R.
Cell Physiol Biochem 2011;27:13-22
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reperfusion period LVDP decreased to 57 ± 5 % of the
pre-ischemic value in non-treated control hearts. Post-
ischemic recovery was improved similarly after all phar-
macological treatments reaching values of ~  75 % of the
pre-ischemic control (Fig. 2, upper panel). A similar pat-
tern was observed when +dP/dtmax values were analyzed
(Fig. 2, lower panel).
The LVEDP (an index of diastolic stiffness) was
approximately 10 mmHg at the end of the stabilization
period in the different experimental groups. This param-
eter significantly increased reaching a value of 26 ± 5
mmHg after 2 hs. of reperfusion. However, this increase
was not detected in any of the treated groups (data not
shown). In other words, myocardial diastolic stiffness of
treated hearts did not significantly change during
reperfusion.
Given that ROS generation and the consequent tis-
sue damage may be responsible for myocardial
reperfusion injury [38, 39], we next determined the im-
pact of the three pharmacological interventions on myo-
cardial TBARS concentration, an index of lipid
peroxidation. Fig. 3 shows that TBARS were ~10 nmol/
g in control ischemic hearts, a value that was significantly
reduced by 10 µmol/L cariporide or 2 mmol/L MPG, but
was unaffected by 1 µmol/L SIL. When SIL was com-
bined with either cariporide or MPG, similar reduction in
TBARS to that obtained with each drug alone was ob-
served (Fig. 3). These results show that though the final
effect (IS reduction) of cariporide, MPG and SIL was of
a similar magnitude, cariporide and MPG decreased myo-
cardial impact of ROS whereas SIL did not. These data
reinforce the idea of an “antioxidant property” of
cariporide, which we [19, 40] and others [41] previously
reported. In order to further analyze the effect of these
compounds on ROS production, we used exogenous
Ang II (1 nmol/L) as a tool to stimulate ·O2
- production in
myocardial tissue slices [42]. Figure 4 shows that whereas
cariporide and MPG blunted the Ang II-induced increase
in ·O2
- production, SIL did not, which is coincident
with the lack of effect of SIL upon myocardial TBARS
(Fig. 3).
Given that the increase in ROS production may
stimulate the ERK1/2- p90RSK kinase pathway leading to
NHE-1 phosphorylation and activation [43-47], we next
analyzed the phosphorylation state of the NHE-1and its
upstream kinases at the end of the reperfusion period.
NHE-1 phosphorylation at Ser703 was estimated by quan-
tifying levels of P-14-3-3 binding motif present on
immunoprecipitated samples, as explained in Methods.
The three pharmacological interventions (cariporide, MPG,
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Fig. 3. Myocardial TBARS concentration was determined
under different experimental conditions as an index of ROS-
mediated lipid peroxidation. TBARS were ~10 nmol/g in con-
trol post-ischemic hearts, a value that was significantly reduced
by cariporide or MPG, but unaffected by SIL. As expected, the
combination of SIL with either cariporide or MPG also reduced
TBARS. These results suggest a miscorrelation between ROS
production and IS and reinforce the notion that cariporide has
an “antioxidant property” not observed after SIL alone.
* P < 0.05 vs. I/R.
Fig. 4. Effect of cariporide, MPG, and SIL on ·O2- production
induced by 1 nmol/L Ang II in isolated myocardial tissue slices.
Incubation with Ang II for 15 minutes caused a significant
increase in ·O2
- production that was, as expected, blunted by
specific AT1 receptor blockade with Losartan (Los), but also
by cariporide and MPG. However, SIL did not exert this effect.
These results clearly agree with the TBARS measurements
after ischemia/reperfusion (Fig. 3) and reinforce the notion of
the “antioxidant property” of the NHE-1 inhibitor, which was
not detected after PDE5A inhibition. Since ·O2
- production
stabilized after 15 minutes as previously reported,37 the data
obtained at this time point were expressed as percent of con-
trol values without additions. Inset shows the lack of effect of
all drugs used upon the basal measurement. * P < 0.05 vs.
control.
Cell Physiol Biochem 2011;27:13-22
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and SIL) induced similar reductions in NHE-1 phosphor-
ylation (Fig. 5). However, while cariporide and MPG
Fig. 6. Proposed chain of events triggered by reperfusion
where both a burst of ROS and Ca2+ overload are not mutually
exclusive events, but steps in the same pathway. In this regard,
the ROS burst appears to be just a triggering factor of the
pathologic process by promoting MAPK-mediated NHE-1 phos-
phorylation, which is responsible for myocardial tissue dam-
aging. Thus, preventing ROS formation either by MPG or
cariporide would prevent cell injury by avoiding NHE-1 activa-
tion, while PDE5A inhibitors would directly target sarcolemmal
NHE-1 phosphorylation without affecting oxidative stress.
Garciarena/Fantinelli/Caldiz/Chiappe de Cingolani/Ennis/Pérez/
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decreased phospho-ERK1/2 and phospho- p90RSK -prob-
ably by preventing ROS formation- these kinases were
unaffected by SIL (Fig. 5). Therefore, though the three
interventions reached the similar endpoint of reducing
NHE-1 phosphorylation while MPG and cariporide
prevented activation of the ROS-sensitive MAPK, SIL
directly targeted NHE-1.
Discussion
In the present study, we provide evidence that three
different pharmacological interventions -cariporide, MPG,
Fig. 5. Increased phosphorylation of ERK1/2 (upper panel),
p90RSK (middle panel), and the 14-3-3 binding motif (lower panel)
was detected in post-ischemia non-treated hearts, effects that
were all blunted by MPG or cariporide. Interestingly, SIL did
not affect the increase in phospho-ERK1/2 and phospho-
p90RSK, but fully prevented the increase in the phospho-Ser
14-3-3 binding motif signalling. Therefore, in spite of a similar
endpoint (reduction in NHE-1 phosphorylation), SIL did not
act through the inactivation of ROS-sensitive kinases upstream
the exchanger, result that agrees with the lack of prevention of
myocardial lipid peroxidation by SIL shown in Fig. 3.* P < 0.05
vs. non-ischemic control.
Cell Physiol Biochem 2011;27:13-22
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and SIL- applied during the early reperfusion phase (first
20 minutes of reflow) decreased IS to a similar extent
(~50 % of that seen in non-treated infarcted hearts) and
that combination of treatments did not induce further re-
duction of IS suggesting a common mechanism of pro-
tection. Postischemic systolic and diastolic function was
equally improved by each treatment. Given that all inter-
ventions converged to a reduction in the estimated
NHE-1 phosphorylation at Ser703, and that phosphoryla-
tion of the exchanger at this site is one of the main path-
ways to activate NHE-1 [26, 45], we suggest that the
exchanger inhibition would be the underlying common
mechanism of protection for the three compounds tested.
A large burst of ROS during the first minutes of
reperfusion has been consistently shown to occur [30-
37]. This increased ROS production could lead to an ex-
tensive oxidative damage resulting in cell death by
apoptosis, necrosis and/or autophagy [48]. However, the
beneficial effects of scavengers or antioxidants in
ischemia/reperfusion are still a matter of controversy (see
ref. [49] for review). It has been proposed that ROS
production early at reperfusion lead to MPTP opening
with a consequent loss of cell viability [50]. Actually, re-
cent reports in animals [51] and patients [52] have shown
protection against reperfusion injury when MPTP for-
mation is inhibited with cyclosporine. Herein, we present
evidence that myocardial damage by lipid peroxidation
(estimated by TBARS) is blunted by MPG and cariporide,
but not by SIL, which would suggest that ROS may not
have deleterious effects per-se, but through kinase acti-
vation leading to NHE-1 phosphorylation. The concept
that the burst of ROS at the beginning of reperfusion
acts through NHE-1 activation deserves further research
directed to analyze the effects of MPTP inhibitors on the
exchanger activity.
The decrease in TBARS and IS induced by MPG
and cariporide were previously reported by us [19]. The
results obtained with cariporide and MPG preventing the
activation of the kinases that phosphorylate the NHE-1
are in line with the previously reported action of ROS on
MAPK activation [44, 47]. NHE-1 inhibition would de-
crease intracellular Na+ concentration and consequently
intracellular Ca2+ thus preventing mitochondrial Ca2+ over-
load.
The experiments performed under PDE5A inhibi-
tion with SIL allowed us to demonstrate a similar protec-
tion in terms of IS reduction but without interfering with
ROS formation at the onset of reperfusion. This conclu-
sion was based on the fact that SIL did not prevent the
increase in TBARS detected after ischemia/reperfusion
(Fig. 3), and it was further supported by the results ob-
tained in isolated tissue slices where SIL was unable to
prevent the Ang II-induced increase in ·O2- production
(Fig. 4).
The activation of the redox-sensitive upstream-
NHE-1 kinases (ERK1/2 and p90RSK) during ischemia/
reperfusion has been previously reported [53]. However,
the ability of the PDE5A inhibitor SIL to prevent NHE-1
phosphorylation under these circumstances without af-
fecting kinase activation but limiting IS represents a novel
finding of the present work. It seems possible that the
increase in ROS production only triggers ERK1/2-p90RSK
activation which in turn promotes NHE-1 phosphoryla-
tion influencing IS with no deleterious effects per se.
In other words, in our current experimental conditions
NHE-1 seems to be the sole culprit of myocardial tissue
damage during reperfusion.
The observed decrease in NHE-1 phosphorylation
(Fig.  5) suggests that PDE5A inhibition exerts an action
upon NHE-1 that is independent of ERK1/2-p90RSK acti-
vation. This finding agrees with recent reports from our
laboratory suggesting that PDE5A inhibition induces
NHE-1 dephosphorylation through a PKG-mediated pro-
tein phosphatase activation [18].
The effectiveness of SIL treatment started at the
beginning of reperfusion to reduce myocardial damaging
without evidence of an “antioxidant effect” constitutes a
novel piece of information. Figure 6 summarizes the pro-
posed chain of events triggered by reperfusion and lead-
ing to myocardial tissue damage, together with the po-
tential sites of action of MPG, cariporide and SIL.
Yet, possible limitations of the present study should
be considered. First, it is known that measurement of IS
by the TTC staining technique is affected by the duration
of reperfusion. In this regard, though the same protocol
was used for the three pharmacological interventions, if
one of the interventions retards the manifestation of necro-
sis more than the others, we could have arrived at erro-
neous conclusions. Second, neither the source nor the
exact type of ROS was determined in the present work.
Mitochondria are a potential source of ROS through their
ability to produce ·O2
- in the electron transport chain. Third,
NHE-1 phosphorylation state was estimated through a
phosphospecific antibody which recognizes the Ser703-
phosphorylated in the 14-3-3 binding motif of the
immunoprecipitated NHE-1. Therefore, we have esti-
mated NHE-1 phosphorylation at Ser703, but not at other
regulatory sites such as Ser770 or Ser771 [54].
In conclusion, we demonstrate in isolated rat heart
that three different pharmacological interventions -
Cell Physiol Biochem 2011;27:13-22
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